Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA: Some Mesh Brands May Lead To More Complications In Breast Reconstruction Patients

Executive Summary

Patients who receive breast reconstructive surgery using some brands of acellular dermal matrix seem to have a higher risk of major complications than those whose surgeries did not use the mesh, says a safety alert from the US FDA.

You may also be interested in...



FDA: 36 Dead From Breast Implant-Associated Lymphoma Since 2019, Hundreds Sickened

The US FDA reports the numbers on women globally who've died or been sickened by two types of breast implant illnesses.

'Do Your Job': To The Dismay Of Patients, FDA Panelists On Breast Implants Advise Better Risk Warnings, Not Recalls

Despite pleas from breast implant patients at a March 25-26 US FDA advisory committee meeting for the agency to take off the market silicone and saline breast implants that have initiated a serious range of symptoms in some women, the panel instead recommended FDA get out stronger public advisories warning of the risks of breast implants and a lymphoma associated with the products.

AdvaMed’s MedTech ’21: Focus On MCIT, MDUFA At Hybrid Meeting

Virtual and in-person events are planned for Washington, DC, and Minneapolis, MN, during the trade group gathering.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel